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Abstract  
 
MicroRNAs (miRNAs) are small non-coding RNA regulators of protein synthesis 
that function as “fine-tuning” tools of gene expression in development and tissue 
homeostasis. Their profiles are significantly altered in neurodegenerative 
diseases such as Alzheimer’s disease (AD) that is characterized by both amyloid-
β (Aβ) and tau deposition in brain. A key challenge remains in determining how 
changes in miRNA profiles translate into biological function in a physiological 
and pathological context. The key lies in identifying specific target genes for 
deregulated miRNAs and understanding which pathogenic factors trigger their 
deregulation.  Here we review the literature about the intricate network of 
miRNAs surrounding the regulation of the amyloid precursor protein (APP) 
from which Aβ is derived by proteolytic cleavage. Normal brain function is 
highly sensitive to any changes in APP metabolism and miRNAs function at 
several steps to ensure the correct APP end product is produced and in the right 
form and abundance. Disruptions in this miRNA regulatory network may 
therefore alter Aβ production, which in turn can affect miRNA expression. 
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Introduction 
 
Over 30 million people suffer from dementia worldwide, with numbers firstly 
dramatically increasing and secondly, with no cure in sight (Ballard et al., 2011). Of 
all dementing disorders, Alzheimer’s disease (AD) is the most prevalent. In the AD 
brain there is a widespread synaptic and neuronal loss that causes a progressive 
decline in memory and other cognitive functions ultimately leading to dementia.  
The AD brain is histopathologically characterized by two types of deposits, 
extracellular amyloid-β (Aβ) plaques and intraneuronal neurofibrillary tangles 
(NFTs), both of which can be visualized with specific dyes and impregnation methods 
(Gotz and Ittner, 2008). Aβ is derived from the Amyloid Precursor Protein (APP). It is 
the major constituent of plaques, while hyperphosphorylated (i.e. abnormally 
phosphorylated) forms of tau constitute the NFTs (Selkoe, 1997). The majority of AD 
cases are sporadic (SAD), with familial (FAD) cases likely accounting for less than 
1%. Here, autosomal dominant mutations have been identified in three genes, in APP 
itself, as well as in presenilin 1 (PSEN1) and 2 (PSEN2) both of which encode a 
component of the enzyme complex that is required to generate Aβ (Bertram and 
Tanzi, 2008). While Aβ deposition is closely associated with the onset of AD, it is the 
tau pathology that correlates better with the severity of dementia (Braak and Braak, 
1995). More specifically, studies in transgenic animals revealed that for Aβ to exert 
its toxic effects tau is required (Ittner and Gotz, 2011, Ittner et al., 2010, Roberson et 
al., 2007).  
The currently prescribed drugs do not halt the neurodegenerative process in 
AD. In fact, their effect on cognition is moderate (Ballard et al., 2011): the 
cholinesterase inhibitors donepezil, rivastigmine and galantamine are licensed for 
mild-to-moderate AD, while memantine is an NMDA receptor antagonist prescribed 
for moderate-to-severe AD. At present alternative therapeutic strategies are being 
tested that aim to prevent the formation and aggregation of the above mentioned 
aggregation-prone peptides and proteins, or to facilitate their clearance (Pasic et al., 
2011). Several of these newer strategies have their foundation in transgenic animal 
models that express familial mutant forms of the proteins that form the aggregates in 
human neurodegenerative disease, such as tau or APP (Gotz and Ittner, 2008). These 
models reproduce the biochemical, histopathological and clinical features of the 
human conditions. Transcriptomic and proteomic approaches have been applied to 
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these models, and again, the functional validation included a side-by-side comparison 
with the human AD brain (David et al., 2005, Hoerndli et al., 2005, Hoerndli et al., 
2004). Regulation of APP is complex, with APP RNA levels and isoforms as well as 
proteolytic processing of APP protein affecting normal brain function and disease 
pathogenesis. Here, we will be focusing on the role of miRNAs and discuss how these 
small RNA species have been incorporated into the complex regulatory network 
surrounding the many aspects of APP metabolism and how a major product of APP 
proteolysis, Aβ, is itself regulating miRNAs.  
 
APP isoforms, APP processing and Aβ species 
 
In humans, APP is expressed as three major isoforms that arise from alternative 
splicing (Figure 1) (Zhang et al., 2011). APP751 and APP770 contain the 56 amino 
acid Kunitz Protease Inhibitor (KPI) domain; both isoforms are widely expressed. In 
contrast, APP695 lacks the Kunitz domain and is found predominantly in neurons. 
APP770 has an additional putative glycosylation domain, OX2, that is not present in 
the two other isoforms (Kitazume et al., 2010). APP is a member of a gene family that 
includes APP-like protein 1 (APLP1) and 2 (APLP2). All three are type I 
transmembrane proteins that are processed in a similar manner. What differentiates 
APP from its two homologues is the presence of the Aβ domain. APP’s physiological 
function has remained largely undetermined although there is accumulating evidence 
for a role in neurite outgrowth and synaptogenesis, axonal transport, transmembrane 
signal transduction, cell adhesion, and calcium metabolism. Together with APLP2, 
APP is synergistically required to mediate neuromuscular transmission, spatial 
learning and synaptic plasticity (Weyer et al., 2011).  
 Full-length APP is synthesized in the endoplasmic reticulum (ER) and then 
transported through the Golgi apparatus to the trans-Golgi-network (TGN), where in 
neurons at steady state the highest concentration of APP is found (Greenfield et al., 
1999, Hartmann et al., 1997, Xu et al., 1997). The Aβ peptide is generated by 
proteolytic cleavage in the ER and Golgi/TGN (Wilquet and De Strooper, 2004). 
While cleavage of APP by α-secretase (the ‘non-amyloidogenic’ pathway) precludes 
Aβ generation as the cleavage site is within the Aβ domain, cleavage first by β- and 
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then by γ-secretase generates the Aβ peptide (the ‘amyloidogenic’ pathway)  (Figure 
1).  
Cleavage of APP by α-secretase generates sAPPα plus the c83 fragment. 
Several members of the ADAM (a disintegrin and metalloproteinase) family possess 
α-secretase-like activity and three of them, ADAM9, ADAM10, and ADAM17, have 
been suggested as the α-secretase. Like APP, they are type I transmembrane proteins 
(Zhang et al., 2011). Upon β-cleavage by the enzyme BACE1, c99 is generated and 
the ectodomain of APP is released as soluble APPβ (sAPPβ). Although only differing 
from sAPPα by lacking the Aβ1-16 region at its carboxy-terminus, sAPPβ has been 
reported to function as a death receptor 6 ligand and to mediate axonal pruning and 
neuronal cell death (Nikolaev et al., 2009). c99 is subsequently cleaved by the  γ-
secretase complex (that is composed of at least four components; presenilin, nicastrin, 
anterior pharynx-defective-1 (APH-1), and presenilin enhancer-2 (PEN-2)), 
generating Aβ. γ-cleavage generates both Aβ40, the major species, and Aβ42, the 
more amyloidogenic species, as well as releases the intracellular domain of APP 
(AICD). γ-Secretase further mediates ζ-site cleavage (Aβ46) (Zhao et al., 2004) as 
well as ε-site cleavage (Aβ49) (Sastre et al., 2001, Weidemann et al., 2002), 
suggesting a sequential cleavage model where cleavage at the ε-site is followed by the 
ζ-site and γ-site (Figure 1). 
Aβ has been implicated in both physiological and pathological functions (Gotz 
et al., 2008). While little is known about its physiological role, a plethora of data are 
available on its aggregation in AD brains where it forms oligomers and fibrils that 
eventually deposit in the extracellular space as amyloid plaques (Gotz et al., 2011, 
Ono et al., 2009, Tomiyama et al., 2010). In sporadic cases of AD, the levels of Aβ 
and in particular of its major amyloidogenic form, Aβ42, are increased either because 
of an increased production or an impaired clearance, by mechanisms that again are 
only poorly understood (Gotz et al., 2008). In familial AD (FAD), increased Aβ levels 
are due to mutations either in the APP gene itself or in the PSEN1 and 2 genes that 
encode subunits of the APP processing machinery (Selkoe and Podlisny, 2002). While 
increased Aβ levels characterize AD pathology, the precise mechanisms and signaling 
cascades that Aβ uses to exert its toxicity are only partly understood (da Cruz e Silva 
et al., 2010, Lim et al., 2010, Palop and Mucke, 2010). With regards to toxicity, an 
additional level of complexity has been added with the identification of species such 
6 
 
as Aβ43 (Saito et al., 2011) or pyroglutamate-modified Aβ42 (Aβ (3(pE)-42) that are 
believed to be even more toxic than Aβ42 itself, and by the fact that Aβ exists in 
different aggregation states that includes oligomeric species (Glabe, 2008, Walsh et 
al., 2002) (Figure 2). As far as down-stream toxicity is concerned, in some 
experimental paradigms such as mitochondrial function, oligomeric and fibrillar Aβ 
were both found to cause a similar degree of toxicity, while monomeric Aβ was not 
toxic (Eckert et al., 2008, Eckert et al., 2008). 
 
MicroRNAs – post-transcriptional regulators of gene expression  
 
MicroRNAs (miRNAs) add yet another level of complexity. They are “fine-tuning” 
tools of gene expression in development and tissue homeostasis. Evolutionary 
conserved, these 19-24 nucleotide-long non-coding RNAs negatively regulate 
expression of specific mRNA targets through base pairing between their “seed 
region” and sequences commonly located in the 3’UTR of their targets (Fabian et al., 
2010, Siomi and Siomi, 2010). Whilst there is perfect to near perfect complementary 
base pairing in plants, in mammalian cells, only a pairing between the seed sequence 
of the miRNA and the 3′ UTR of the mRNA target is thought to be important (Hebert 
and De Strooper, 2009, Vilardo et al., 2010, Wang et al., 2010). Deep sequencing 
revealed that there are over 1400 miRNA genes in the human genome whereas in the 
mouse they are in the order of around 700 (miRBase.org). Of these, approximately 
300 are expressed in mouse brain (Landgraf et al., 2007). It is estimated that each 
miRNA can target up to several hundred to a thousand transcripts, but unfortunately 
only a very few targets have been confirmed in vivo so far (Lau and de Strooper, 
2010). The recent years have seen an explosion in studies linking miRNAs to 
pathological processes, and evidence is mounting that they have a role in 
neurodegenerative diseases ranging from AD to Parkinson’s disease (Kim et al., 
2007) and ALS (Williams et al., 2009). 
 How do miRNAs silence gene expression? The primary miRNA transcripts 
(pri-miRNAs) are transcribed by RNA polymerase II and can be several thousand 
bases in length (Lee et al., 2004). In the nucleus, these transcripts are processed by the 
Drosha/DGCR8 complex to produce so-called precursor miRNAs (pre-miRNAs), 
which are approximately 70 nucleotides in length and characterized by a stem-loop 
structure. After nuclear export by Exportin 5/Ran, pre-miRNAs are cleaved in the 
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cytoplasm by Dicer, an enzyme for which neuronal cell-type-specific knock-out 
mouse strains are available (Cuellar et al., 2008, Davis et al., 2008, Kim et al., 2007, 
Schaefer et al., 2007), to generate mature miRNAs. These bind to the 3′UTR of 
mRNA targets, recruiting the RNA induced silencing complex (RISC) that inhibits 
the expression of the bound mRNA target (Mathonnet et al., 2007, Wakiyama et al., 
2007). While Dicer cleaves the pre-miRNAs, the Argonaute (Ago) proteins in the 
RISC bind the miRNAs and mediate gene silencing (O'Carroll et al., 2007). 
Determining how changes in miRNAs expression levels translate into 
biological function remains a challenge; the key lies in identifying specific target 
genes for deregulated miRNAs and understanding which pathogenic factors trigger 
their deregulation (Schonrock et al., 2011). This is particularly true for 
neurodegenerative diseases where one finds a network of interactions, with miRNAs 
regulating key mRNAs such as APP, while one of APP’s prime proteolytic products, 
Aβ, regulates a myriad of miRNAs which in turn can create a feed-back regulatory 
loop on APP transcript levels. 
 
De-regulation of miRNAs in AD brain 
 
It took seven years after discovering the first human miRNAs (Pasquinelli et al., 
2000) until the first report of differential miRNA profiles was published for human 
AD tissue (Lukiw, 2007). Since then several groups have performed genome-wide 
profiling of AD tissue highlighting AD-specific changes in the miRNA regulatory 
system (Hebert et al., 2008, Nunez-Iglesias et al., 2010, Shioya et al., 2010, Wang et 
al., 2008). These may either involve neuronal or glial cells or both, as both cell types 
are affected in human ‘neurodegenerative’ conditions (Kurosinski and Gotz, 2002). 
miRNA profiling of human cortical tissue identified thirteen ‘AD-specific’ miRNAs 
that are down-regulated in human AD brain (Cogswell et al., 2008, Hebert et al., 
2008). The subsequent generation of mice with a neuronal knockout of Dicer is a 
proof-of-principle that miRNAs are likely to play a role in neurodegeneration (Davis 
et al., 2008, Hebert et al., 2010, Shin et al., 2009). However, miRNA expression 
studies on AD patients have revealed either no or only very little overlap in miRNA 
changes (Hebert and De Strooper, 2009). To remove the complexity inherently 
associated with human studies tissue culture and animal model systems have been 
used to dissect pathomechanisms (see below). These studies have replicated many of 
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the changes observed in human AD brain, thus underscoring the validity of model 
systems in gaining a better understanding of the pathogenesis of AD. 
 
Direct regulation of the APP mRNA by miRNAs 
 
As miRNAs are known to have in the order of hundreds of putative mRNA target 
genes, which in addition tend to contain binding sites for more than one miRNA 
species adding to possible combinatorial effects, a major challenge is firstly to link 
distinct miRNAs to distinct mRNA targets in vivo and secondly to determine whether 
such a binding has an affect on protein levels. With regards to AD, a major question is 
whether miRNAs are capable of altering Aβ levels. Most miRNA studies involving 
AD-related genes rely on luciferase-based reporter gene assays using 3’ UTR fusion 
constructs with intact (and mutated) miRNA binding sites. In the AD field there are a 
few obvious targets, which includes APP (Figure 2). Help comes from C. elegans, 
where the worm homolog of APP, APL-1, is developmentally regulated by the 
miRNA Let-7 (Niwa et al., 2008).  
Several miRNAs have been identified in vitro to directly regulate APP. They 
include miR-106a, -520c (Patel et al., 2008) as well as members of the miR-20a 
family, such as -20a, -106a/b and -17 (previously referred to as miR-17-5p, 
http://www.mirbase.org) (Hebert et al., 2009), miR-16 and -101 (Long and Lahiri, 
2011, Vilardo et al., 2010) and most recently miR-147, -655, -323-3p and -153 (Delay 
et al., 2011). Whilst miR-106b and miR-101 have been shown to be down-regulated 
in AD brain, therefore potentially contributing to increased APP expression and Aβ 
generation (Hebert et al., 2008, Nunez-Iglesias et al., 2010),  it remains to be 
determined which of these miRNAs actually regulates APP in vivo. Interestingly, AD-
specific polymorphisms identified in the APP 3’UTR (T171C and A454G) affect the 
APP-modulating activity of miR-147 and -20a, respectively, and could therefore 
affect AD risk via altering miRNA-mediated regulation of APP expression (Delay et 
al., 2011). 
Whilst, the majority of observed miRNA regulatory binding sites are located 
in the 3’UTRs of mRNAs, effective miRNA binding sites have also been identified in 
open reading frames and 5’UTRs of target mRNAs (Duursma et al., 2008, Forman et 
al., 2008, Jopling et al., 2005, Orom et al., 2008, Tay et al., 2008). The APP 5’UTR 
plays fundamental roles in APP regulation and biogenesis (Lahiri et al., 2005, 
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Maloney et al., 2004, Rogers et al., 2002) and although no miRNAs have so far been 
reported to target the APP 5’UTR, it remains an interesting possibility. 
 
Regulation of APP alternative splicing by miRNAs 
  
Changes in neuronal APP isoform expression are associated with an increase in Aβ 
production (Donev et al., 2007), and increases of exon 7 and/or 8 containing APP 
isoforms have been reported in various regions of AD brain. A very recent study 
reveals a contribution of miRNAs to yet another level of APP regulation, alternative 
splicing (Figure 2) (Smith et al., 2011). Exon 7 of APP encodes the KPI domain, 
while exon 8 encodes the OX2 domain, with the neuron-enriched APP695 form 
lacking both domains (Figure 1). The new study found that the lack of miRNAs in 
post-mitotic neurons in vivo (achieved via a Dicer knockout) was associated with 
exon 7 and 8 inclusion (Smith et al., 2011). This indicates that miRNAs expressed in 
post-mitotic neurons in vivo participate in the physiological regulation of APP mRNA 
splicing. Given the potentially important role of miR-124 in neuronal maintenance 
and splicing (Makeyev et al., 2007, Papagiannakopoulos and Kosik, 2009), the 
authors suggest that loss of this miRNA could be responsible for the above effects 
possibly through the regulation of its target gene, polypyrimidine tract binding protein 
1 (PTBP1). 
They further found that ectopic expression of miR-124 reversed the above 
effects on APP splicing in cultured neurons. Interestingly, miR-124 levels are reduced 
in AD (Lukiw, 2007, Smith et al., 2011). Whether these reflect selective neuronal loss 
remains to be seen but it is intriguing to assume that specific neuronal miRNAs 
regulate APP splicing. 
 
Indirect regulation of APP processing by miRNAs 
 
In addition to APP, the β-secretase BACE1 has been identified as a miRNA target 
(Figure 2). Loss of the miRNA cluster containing miR-29a, -29b1 and -9 in SAD has 
been found to correlate with an increased BACE1 expression (and by extension, 
increased Aβ levels) (Hebert et al., 2008). More recently, miR-29c was shown to 
lower BACE1 protein levels in vitro, and miR-29c-overexpressing mice down-
regulated BACE1 levels suggesting that miR-29c might be an endogenous BACE1 
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regulator (Zong et al., 2011). FAD5 mice are a transgenic mouse strain with elevated 
BACE1 levels and early-onset plaque formation; in these mice the above-mentioned 
three miRNAs are not increased (O'Connor et al., 2008). Likewise, when a second 
APP mutant strain, Tg2576, was energy-deprived this caused an increase in miRNAs -
29a and –b1, which would have been expected to cause a concomitant decrease in 
BACE1 expression, which however was not found (O'Connor et al., 2008).  Yet, the 
final word on BACE1 regulation is not spoken, as energy deprivation could affect 
additional miRNAs that could either directly or indirectly feed-back on BACE1 
expression levels. In fact this example avidly demonstrates the difficulties one 
encounters in studying a system as complex as the miRNA network. 
Another study in an APP/PS1 mutant mouse model of AD revealed an inverse 
correlation between BACE1 protein levels and two miRNAs (miR-298 and -328) and 
showed these two miRNAs directly interacted with the BACE1 3’UTR in mouse cell 
lines (Boissonneault et al., 2009). Whether additional miRNAs are deregulated 
remains to be determined. Finally, in APP mutant Tg19959 mice, BACE1 levels were 
increased while miR-103 and -107 levels were decreased (Faghihi et al., 2008), 
however whether there is a direct relationship or not remains to be elucidated. 
 
Down-stream effects of Aβ on miRNA expression  
 
An interesting finding of both transcriptomic and proteomic studies is the 
complementarities of cellular and transgenic mouse models as they often reveal a 
significant overlap in deregulated genes and proteins, respectively (David et al., 
2006). We analysed the effect of Aβ itself on miRNA expression in different 
experimental systems and found again a remarkable overlap. When primary 
hippocampal neurons were incubated with fibrillar preparations of Aβ42, we found 
that this invoked a strong change in miRNA profiles with a substantial proportion of 
miRNAs being down-regulated (Schonrock et al., 2010). This response was rapid. We 
validated nine miRNAs (miR-9, -181c, -148b, -30c, -20b, -361, -21, -409-3p and Let-
7i) as being down-regulated by aged Aβ42 (Schonrock et al., 2010).  
 Interestingly, the miRNA down-regulation in Aβ-treated hippocampal neurons 
was paralleled in the hippocampus of Aβ-plaque forming APP23 mice at the onset of 
plaque formation. Some of the deregulated miRNAs in our study became affected 
prior to Aβ plaque formation (such as miR-409-3p and Let-7i) similar to what is seen 
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in a related study (Wang et al., 2009). Furthermore, the expression of certain miRNAs 
changed over time (from up- to down-regulated or vice versa), supporting the 
transient effect on miRNA expression during AD development. Biological pathways 
affected by predicted miRNA target genes such as axon guidance, mitogen-activated 
protein kinase (MAPK) signaling, TGFβ signaling, glutamate metabolism, long term 
potentiation, and regulation of the actin cytoskeleton are intricately associated with 
proper brain function relevant to AD.  miRNAs -181c, -9, -30c, -148b, -20b and Let7i 
are particularly interesting as these are also down-regulated in human AD brain 
(Cogswell et al., 2008, Hebert et al., 2008).  
 miR-9 is the most abundant human brain miRNA (Mattick and Makunin, 
2005) and a recurring candidate from several AD profiling studies. Studies performed 
in zebrafish and mice revealed that it is essential in patterning, neurogenesis and 
differentiation and thus ideally placed to impact various aspects of brain function. 
Over-expression of miR-9 accelerates neuronal differentiation, while its inhibition in 
the medial pallium of embryonic day 11.5 mouse embryos results in defective 
differentiation of Cajal-Retzius cells, the first neurons to populate the embryonic 
cortex. Similarly, loss of miR-9 in zebrafish embryos decreases the relative numbers 
of differentiated neurons in the anterior hindbrain (Leucht et al., 2008, Shibata et al., 
2008, Zhao et al., 2009). Neurogenesis is not only important in the developing brain 
but is a process which continues in the adult hippocampus, a region heavily affected 
by Aβ pathology in AD (Hallbergson et al., 2003). Interestingly, AD patients exhibit 
altered expression of early neuronal markers in the hippocampus, which has been 
attributed to increased neurogenesis (Jin et al., 2004). Decreased expression of miR-9 
may therefore impact adult brain function. 
Global miRNA profiles have also been established from APP mutant mice that 
both over-express human APP and accumulate Aβ. Compared with the use of 
synthetic Aβ, there is a confounding effect of increased AICD production. In an 
APP/PS1 double mutant mouse model, of 37 differently expressed miRNAs, several 
(miR-20a, -29a, -125b, -128a, and -106b) were down-regulated, while others (miR-
34a, let-7, miR-28 and -98) were up-regulated, with miR-29a and 106b showing the 
same direction of changes as seen in AD brain (Wang et al., 2009). miRNA 
quantitative RT-PCR showed that miR-106b is up-regulated in 3-month-old APP/PS1 
mice and down-regulated at 6 months (Wang et al., 2010). While these studies suggest 
a possible transient effect of Aβ plaque pathology on miRNA (miR-106b) expression, 
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miR-106b also regulates APP mRNA levels (Hebert et al., 2009) thus creating a 
possible regulatory feedback loop.  
 
Role of miRNAs in AD – fine-tuning versus decisive role 
 
A major challenge in general and in neurodegeneration in particular is in 
linking deregulated miRNAs to their mRNA targets, as so far only a few selected 
targets have been identified that include APP, BACE1 and  the α-synuclein-encoding 
SNCA (Lau and de Strooper, 2010). At present, target prediction relies on algorithms 
such as miRBase, PicTar, miRanda, PITA or TargetScan with the latter showing the 
most accurate predictions upon target validation (Baek et al., 2008, Selbach et al., 
2008). One approach to circumvent this inherent problem is to over-express or inhibit 
individual miRNAs and analyze protein levels by using proteomics approaches such 
as stable-isotope labeling with amino acid in cell culture (SILAC) (Baek et al., 2008, 
Selbach et al., 2008). Another option is co-immunoprecipitating mRNA targets with 
the Argonaute protein Ago2 combined with high-throughput sequencing of RNAs 
isolated by crosslinking immunoprecipitation (HITS-CLIP) (Chi et al., 2009). 
Furthermore, with the advent of the Zinc Finger Nuclease technology it is now 
possible to directly dissect the role of miRNAs in neuronal function and 
neurodegenerative disorders, by manipulating specific miRNA binding sites in situ. 
An ultimate challenge however will be an integrated view of APP/Aβ regulation that 
takes into account the role of miRNAs, mRNA transcription, translation, 
posttranslational modifications, subcellular compartmentalization, brain regional 
differences and changes over time, both under physiological and pathological 
conditions. This will determine whether miRNAs are merely fine-tuning instruments 
as far as the major players in AD are concerned or whether they indeed play a 
decisive role. In addition it seems that the miRNA network in AD is tightly regulated 
by feedback loops. 
 
Exploiting miRNAs as diagnostic tools in AD 
 
The diagnosis of AD, while only 90% accurate, typically includes an assessment of 
the medical and medication history, a physical examination, blood tests to rule out 
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diabetes, cancer and other conditions, a neuropsychological examination, and 
increasingly, imaging techniques (such as magnetic resonance imaging, MRI, or 
positron emission tomography, PET) as well as measuring biomarkers in either CSF 
(cerebrospinal fluid) or blood. Especially CSF biomarkers are currently being 
considered for inclusion in revised diagnostic criteria for research and/or clinical 
purposes to increase the certainty of ante mortem diagnosis of AD. These include 
platforms such as the INNOTEST enzyme-linked immunosorbent assay or the INNO-
BIA AlzBio3, for measurement of CSF Aβ and tau proteins, both total and 
phosphorylated at epitope Thr181 (AT270) (Fagan et al., 2011). As lumbar punctures 
are quite invasive there is a trend in the field to move into plasma as the changes in 
Aβ levels reported for CSF are also reflected by according changes in plasma 
(Lewczuk et al., 2010). With regards to miRNAs these are readably detectable in 
bodily fluids, making them attractive biological markers. In addition, they are in 
general quite stable. So far however only a few groups have explored the role of 
miRNAs in blood and CSF, with the deregulated brain miRNAs having roles in 
known and novel pathways in AD pathogenesis related to amyloid processing, 
neurogenesis, insulin resistance, and innate immunity (Cogswell et al., 2008). By 
analyzing blood mononuclear cells of patients with SAD, miRNAs -34a and -181b 
were found to be significantly up-regulated in AD subjects and confirmed by 
quantitative PCR, however more work needs to be invested and the finding replicated 
using a bigger sample size (Schipper et al., 2007). 
 
Using miRNAs in AD therapy 
 
In addition to diagnostics, miRNAs might also be used in therapy. As discussed 
above, there are at present only four FDA-approved drugs available whose efficacy 
however is modest. Patients are further treated with antipsychotic drugs although the 
benefits are moderate and are accompanied by severe side effects such as sedation and 
Parkinsonism (Ballard et al., 2009, Ballard and Howard, 2006). To combat depression 
in people with AD antidepressant therapies are pursued (Weintraub et al., 2010). 
Finally, anticonvulsants are used off license as an effective treatment of agitation and 
aggression (Ballard et al., 2009). There is therefore a need for alternative strategies. 
Among the proposed disease-modifying treatments are immunotherapy, along with 
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secretase inhibitors, amyloid and tau aggregation inhibitors, copper/zinc modulators, 
lithium as an inhibitor of the tau kinase GSK3 as well as natural products and 
vitamins (Ballard et al., 2011). Given the role of miRNAs in regulating APP levels, 
splicing and Aβ metabolism it is well possible that they may emerge as therapeutic 
reagents. As tau is also subjected to alternative splicing in addition to a high degree of 
posttranslational modifications (Chen et al., 2004), it would not be surprising that this 
protein, that constitutes the second hallmark lesion of AD, the NFTs, would also be 
regulated by miRNAs. Indeed, tau hyperphosphorylation is affected in part by the 
kinase Erk1, which in turn is directly regulated by the miR-15 family, which is down-
regulated in AD (Hebert et al., 2010). The near future will determine which role 
miRNAs play in neurodegeneration and to which extent they can be exploited as 
diagnostic and therapeutic tools. 
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Figure legends  
 
Figure 1. Schematic drawing of the Amyloid Precursor Protein (APP) and its 
processing pathways. In humans, APP exists in three major isoforms that are 
generated by alternative splicing and differ mainly by the presence or absence of the 
Kunitz-type protease inhibitor (KPI) and OX2 homology domains. APP can be 
processed by α-secretase in a non-amyloidogenic pathway, which precludes the 
formation of Aβ and generates soluble APPα (sAPPα) and a C-terminal fragment 
(c83). Alternatively, in the amyloidogenic pathway, cleavage by the β-secretase 
BACE1 generates soluble APPβ (sAPPβ), which is secreted, and a C-terminal 
fragment (β-CTF or c99). Subsequent cleavage of c99 by the γ-secretase complex 
generates Aβ and the APP intracellular domain (AICD) which can be further cleaved 
by caspases to produce a c31 fragment. 
 
Figure 2. The miRNA network surrounding APP has both upstream and downstream 
components which directly or indirectly affect APP (not drawn to scale) processing 
and Aβ metabolism. miR-124 affects the generation of APP mRNA isoforms via 
alternative splicing, whilst a range of miRNAs target APP mRNA directly via its 
3’UTR thus impacting APP translation efficiency. APP is also regulated indirectly by 
a host of miRNAs, which affect APP processing via targeting the BACE1 (β-
secretase) mRNA. This level of regulation affects the type of Aβ species produced, 
which differ in their degrees of toxicity. Aβ40 is the major species, whilst Aβ42 is the 
major amyloidogenic species. However, longer and shorter Aβ versions exist (such as 
Aβ38 and Aβ43) or forms that are pyroglutamate-modified at their amino-terminus 
(Aβ(3pE)). Furthermore, Aβ can exist as a monomer, as higher order aggregates (such 
as in oligomers or ADDLs, Amyloid β-Derived Diffusible Ligands) or as fibrils. 
Fibrillar Aβ is the major constituent of amyloid plaques. Aβ itself causes a 
deregulation of neuronal miRNAs, several of which have feedback loops, which in 
turn affect APP metabolism and Aβ generation. 
 
 
 


